Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 26, 2021, titled "Glenmark becomes the first company to launch Remogliflozin + Vildagliptin +Metformin fixed dose combination, at an affordable price for adults with Type 2 Diabetesin India".